Co-Chairman
George Wilding is currently Director of the Paul P. Carbone Comprehensive Cancer Center and Anderson Professor of Clinical Oncology of the Department of Medicine of UW-Madison and an internationally recognized leader and clinician in the fields of prostate cancer prevention and therapy. He is a member of the Editorial Board of the Journal “The Prostate” and is recognized as a world expert in prostate disease.
Dr. Wilding is the principal inventor of the CPC-100 prostate cancer therapeutic drug and a major collaborator with Hirak Basu in the development of CPC-200. As the current University of Wisconsin Paul P. Carbone Comprehensive Cancer Center Director of Clinical Research, he oversees peer-reviewed cancer research funding at UWCCC. The UWCCC’s greatest strength is its involvement in groundbreaking clinical trials and research studies conducted to answer specific scientific questions about new ways to diagnose and treat cancer. They have over 30 years experience in conducting cancer clinical trials. .
Dr. Wilding graduated from the University of Massachusetts Medical School where he also completed his training in Internal Medicine. He underwent training in Medical Oncology at the National Cancer Institute. He joined the UW School of Medicine and Public Health faculty to focus on the development of new cancer therapies, particularly aimed at progressive and advanced prostate cancer.
.
